Sector: Health Care
Director information for BIOGEN INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Christopher A. Viehbacher | President and Chief Executive Officer | 66 | ["Executive Leadership and Business Operations","Commercial","Drug Development","Healthcare and Pharma Leadership","Finance and Accounting","International Business","Public Board Service","Government and Public Policy","extensive international experience in both large pharmaceutical companies and entrepreneurial biotech companies","understanding of the complexities involved in running a multibillion-dollar global pharmaceutical business","appreciation for the value of innovation"] | [] | 2026 |
| Eric K. Rowinsky | 69 | [] | ["Audit Committee","Corporate Governance Committee","Compensation and Management Development Committee"] | 2026 | |
| Eric K. Rowinsky, M.D. | President | 69 | ["Executive Leadership and Business Operations","Drug Development","Healthcare and Pharma Leadership","Public Board Service","Medicine and Scientific Research"] | ["Compensation and Management Development","Corporate Governance"] | 2026 |
| Jesus B. Mantas | fmr. Global Managing Partner, IBM Business Transformation Services | 57 | ["Executive Leadership and Business Operations","Commercial","Information Technology/Cybersecurity/AI","Public Board Service","International Business","Government and Public Policy","Over 30 years of experience in global business operations","Expertise in data science and artificial intelligence","Gained experience through global strategy and operating management roles"] | ["Compensation and Management Development (Chair)"] | 2026 |
| Lloyd Minor | 68 | [] | [] | 2026 | |
| Lloyd Minor, M.D. | Dean of the Stanford University School of Medicine | 68 | ["Executive Leadership and Business Operations","Drug Development","Cybersecurity","Healthcare and Pharma Leadership","Finance and Accounting","Government and Public Policy","Medicine and Scientific Research","Dean of the Stanford University School of Medicine since 2012","Vice President for Medical Affairs at Stanford University since 2023","Provost and Senior Vice President for Academic Affairs at Johns Hopkins University (2009–2012)","Director of the Department of Otolaryngology – Head & Neck Surgery at Johns Hopkins University (2003–2009)","Board member of Caris Life Sciences, Inc. since 2021","Sc.B. from Brown University","M.D. from Brown University"] | ["Audit"] | 2026 |
| Maria C. Freire | 71 | [] | ["Audit Committee","Corporate Governance Committee","Compensation and Management Development Committee"] | 2026 | |
| Maria C. Freire, Ph.D. | Independent Chair (after 2026 Annual Meeting) | 71 | ["Executive Leadership and Business Operations","Drug Development","Healthcare and Pharma Leadership","Finance and Accounting","International Business","Public Board Service","Government and Public Policy","Medicine and Scientific Research","Significant knowledge and experience with respect to medical research","Expertise in pharmaceutical industry and government healthcare policymaking","Strong public policy and government experience"] | ["Compensation and Management Development","Corporate Governance"] | 2026 |
| Menelas Pangalos | 59 | [] | [] | 2026 | |
| Monish Patolawala | CFO | 56 | ["Executive Leadership and Business Operations","Commercial","Information Technology/Cybersecurity/AI","Finance and Accounting","International Business","Government and Public Policy","More than 25 years of experience in leading financial operations and business for global industrial and healthcare companies","Oversight of global finance and accounting, global business services, global technology and enterprise strategy functions at Archer-Daniels Midland","Experience enhances the Board’s perspectives on financial and business operations, technology and strategy","CFO, Archer-Daniels Midland (since 2024)","President and CFO, 3M Company (2020 – 2024)","CFO of GE Healthcare (2015 – 2020)","Variety of roles of increasing responsibility at General Electric Company (1994 – 2020)","Chartered Accountant from the Institute of Chartered Accountants of India","Cost and Works Accountant from the Institute of Cost and Works Accountants of India","B. Com from St. Joseph’s College of Commerce (Bangalore, India)"] | ["Audit"] | 2026 |
| Sir Menelas (Mene) Pangalos | Director | 59 | ["Executive Leadership and Business Operations","Commercial","Drug Development","Healthcare and Pharma Leadership","International Business","Public Board Service","Government and Public Policy","Medicine and Scientific Research","Over 30 years of experience in pharmaceuticals and biotechnology","Expertise in corporate strategy and risk management"] | ["Compensation and Management Development"] | 2026 |
| Stephen A. Sherwin | 77 | [] | ["Audit Committee"] | 2026 | |
| Stephen A. Sherwin, M.D. | Clinical Professor of Medicine at UCSF | 77 | ["Executive Leadership and Business Operations","Drug Development","Healthcare and Pharma Leadership","Finance and Accounting","Public Board Service","Government and Public Policy","Medicine and Scientific Research"] | ["Audit"] | 2026 |
| Susan K. Langer | Founding President & Chief Business Officer at Souffle Therapeutics | 35 | ["Executive Leadership and Business Operations","Commercial","Drug Development","Healthcare and Pharma Leadership","Significant experience and knowledge of the biopharmaceutical industry","Deep connections within the biotechnology, start-up and venture capital ecosystems"] | ["Compensation and Management Development"] | 2026 |
| William A. Hawkins | fmr. Chairman and Chief Executive Officer | 72 | ["Executive Leadership and Business Operations","Commercial","Healthcare and Pharma Leadership","Finance and Accounting","International Business","Public Board Service","Government Public Policy","significant executive and board leadership experience in the healthcare industry"] | ["Audit Committee","Corporate Governance Committee","Audit","Corporate Governance"] | 2026 |
